Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Rungroj KrittayaphongUnchalee PermsuwanPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
At the local Thai threshold of 4773.27 USD/QALY, empagliflozin is a cost-effective add-on treatment for patients with HFrEF, but not for patients with HFpEF.